Industry
-
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study
Source: Praxis Precision Medicines
Industry
-
Veneno Technologies Announces Joint Research Agreement with Sumitomo Pharma
Source: Veneno Technologies
Industry
-
Maxion Therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “hard-to-treat” autoimmune diseases
Source: Maxion Therapeutics
Industry
-
BELLUS Health Announces Positive Results from its Phase 1 Camlipixant Study
Source: BELLUS Health
Industry
-
Axalbion to Present Promising Phase 2 Clinical Data in Chronic Cough with AX-8, a Novel TRPM8 Agonist
Source: Axalbion
Industry
-
NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering
NRx Pharmaceuticals
Industry
-
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
Source: QurAlis
Industry
-
Praxis Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor
Source: Praxis Precision Medicines
Industry
-
Maxion Therapeutics raises $16 million to develop novel biologics targeting ion channels and GPCRs
Source: Maxion Therapeutics
Industry
-
FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone
Source: Sage Therapeutics
Industry
-
Karuna Therapeutics to obtain global development, manufacturing, and commercialization rights to Goldfinch Bio’s investigational TRPC4/5 channel candidates.
Source: Karuna Therapeutics
Industry
-
Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities
Source: SB Drug Discovery
Industry
-
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
Source: Catalyst Pharmaceuticals
Industry
-
Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments
Source: PRNewswire
Industry
-
Sionna Therapeutics Announces IND Clearance and Phase 1 Initiation for SION-638 in Cystic Fibrosis
Source: Sionna Therapeutics
Industry
-
Bionomics’ Social Anxiety Disorder Lead Candidate Failed to Hit the Primary Endpoint in Phase 2 Study
Source: Bionomics
Industry
-
Praxis Precision Medicines partners with UCB to discover potential treatments for KCNT1-related epilepsies
Source: Praxis Precision Medicines
Industry
-
Relmada’s lead candidate REL-1017 (NMDAR blocker) did not achieve its primary endpoint in a Phase III study, evaluating it as an adjunctive treatment for MDD
Source: Relmada Therapeutics
Industry
-
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
Source: Algernon Pharmaceuticals
Industry
-
Metrion Biosciences and The KCNC1 Foundation collaborate on development of new ion channel modulators for ultra-rare genetic disorder
Source: Metrion Biosciences
Industry
-
Metrion Biosciences invests in new High Throughput Screening capability and expanded facilities
Source: Metrion Biosciences
Industry
-
Gate Neurosciences Doses First Subject in a Translational EEG Biomarker Study of Apimostinel, a Rapid-Acting Treatment for Acute Depressive Disorders
Source: Gate Neurosciences
Industry
-
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
Source: Axsome Therapeutics
Industry
-
Kriya acquires Redpin Therapeutics, adding its ion channel-based chemogenetics platform and pipeline to gene therapy engine
Source: Kriya Therapeutics
Industry
-
Sophion Bioscience and Sussex Drug Discovery Centre strengthen collaboration
Source: Sophion Bioscience
Industry
-
Relmada Therapeutics reported a Phase III fail for its lead NMDAR blocker, REL-1017, in major depressive disorder
Source: Relmada Therapeutics
Industry
-
Adult mammalian cardiomyocytes successfully recorded for the first time on a high throughput automated patch clamp system
Source: Nanion Technologies
Industry
-
Biohaven Sets New Course with $258 Million in Cash and Deep Pipeline to Advance Science for Patients
Source: Biohaven
Industry
-
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of IND Application for NP-300 (Lechlemer)
Source: Jaguar Health
Industry
-
FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis
Source: NMD Pharma
Industry
-
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for CNS Diseases
Source: Gate Neurosciences
Industry
-
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
Source: Aerie Pharmaceuticals
Industry
-
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of its TRPM8 agonist AR-15512 for the Treatment of Dry Eye Disease
Source: Aerie Pharmaceuticals
Industry
-
The SyncroPatch 384 from Nanion has been installed at the MBExC Cluster of Excellence at the University Medical Centre Göttingen
Source: Nanion Technologies
Industry
-
Metrion Biosciences appoints Dr Benedetta Montagnini as Head of European Business Development
Source: Metrion Biosciences
Industry
-
Newron shows encouraging results for evenamide (Nav channel inhibitor) in patients with treatment-resistant schizophrenia
Source: Newron Pharmaceuticals
Industry
-
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
Source: Aerie Pharmaceuticals
Industry
-
NMD Pharma expands its US presence with the creation of NMD Pharma US, Inc.
Source: NMD Pharma
Industry
-
The SyncroPatch 384 from Nanion is installed at the FDA for cardiac safety pharmacology studies
Source: Nanion Technologies
Industry
-
Bridge Biotherapeutics Enters into an Option-to-License Agreement with CellionBioMed to Develop BBT-301 for the Treatment of Multiple Fibrotic Diseases
Source: Bridge Biotherapeutics
Industry
-
David Clapham joins Caraway Therapeutics as a scientific advisor
Source: Caraway Therapeutics
Industry
-
Morphoceuticals Inc. Hails Successful Limb Regeneration in Adult Frogs
Source: Business Wire
Industry
-
CalciMedica Initiates CARDEA-Plus: A Clinical Trial of Auxora™ in Patients with Critical COVID-19 Pneumonia
Source: CalciMedica
Industry
-
Sophion introduced QPatch Compact – a new bench-top semi-automated patch clamp system
Source: Sophion Bioscience
Industry
-
Metrion Biosciences and Bioqube Ventures collaborate to identify Kv1.3 inhibitors for autoimmune disorders
Source: Metrion Biosciences
Industry
-
Metrion Biosciences expands ion channel drug discovery service capabilities and in-house expertise
Source: Metrion Biosciences
Industry
-
Metrion Biosciences appoints Rory Curtis as Vice President US Commercial Operations
Source: Metrion Biosciences
Industry
-
Metrion Biosciences expands into new headquarters to support continued growth
Source: Metrion Biosciences
Industry
-
Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development
Source: Metrion Biosciences
Industry
-
Saniona initiates Phase 1 clinical trial of SAN711 for the treatment of rare neuropathic disorders
Source: Saniona
Industry
-
Sophion Bioscience and Genedata Announce New Genedata Ready-to-Run Partnership
Source: Sophion Bioscience
Industry
-
Caraway Therapeutics and AbbVie join forces to develop novel TMEM175 modulators for Parkinson’s disease and other neurodegenerative disorders
Source: Caraway Therapeutics
Industry
-
Metrion Biosciences appoints Mark Keogh as Non-Executive Director
Source: Metrion Biosciences
Industry
-
Metrion Biosciences raises £2.7m and adds GLP cardiac safety services to the suite of ion channel drug discovery services
Source: Metrion Biosciences
Industry
-
CalciMedica Raises $21 Million in Series D Financing to support the clinical development of CRAC channel inhibitors
Source: CalciMedica
Industry
-
Soleno Therapeutics collaborates with Vanderbilt University to discover and develop novel KATP channel activators for the treatment of rare diseases
Source: Soleno Therapeutics
Industry
-
Metrion Biosciences appoints John Montana as Non-Executive Director
Source: Metrion Biosciences
Industry
-
Metrion Biosciences collaborates with Sosei Heptares to Explore Structure-based Drug Discovery Approaches to Ion Channels
Source: Metrion Biosciences
Industry
-
